Amgen Prostate Cancer Data May Boost Sales $2 Billion

Loading player, please wait...

Recommended Videos

  • Info

  • Comments

Dec. 14 (Bloomberg) -- Amgen Inc.’s denosumab, which is marketed as Xgeva, delayed the spread of prostate cancer to men’s bones in a study that may help boost sales by $2 billion a year. The company’s shares rose in early trading. Bloomberg's Shannon Pettypiece reports. (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change